Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EQ 101

Drug Profile

EQ 101

Alternative Names: BNZ-1; BNZ132-1; BNZ132-1-40; EQ-101

Latest Information Update: 10 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bioniz
  • Developer Bioniz; Equillium
  • Class Antineoplastics; Antivirals; Peptides; Skin disorder therapies
  • Mechanism of Action Interleukin 15 inhibitors; Interleukin 15 receptor antagonists; Interleukin 2 inhibitors; Interleukin 2 receptor antagonists; Interleukin 9 inhibitors; Interleukin 9 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Cutaneous T-cell lymphoma
  • Phase II Alopecia areata; Large granular lymphocytic leukaemia; T-cell leukaemia
  • Research Vitiligo
  • No development reported Adult T-cell leukaemia-lymphoma; Tropical spastic paraparesis

Most Recent Events

  • 04 Jun 2024 Updated efficacy and adverse event data from a phase II trial in Alopecia areata released by Equillium
  • 30 Apr 2024 Equillium completes a phase II trial in Alopecia areata in Australia and New Zealand (IV) (NCT05589610)
  • 21 Dec 2023 Adverse events data from a phase II trial in Alopecia areata released by Equillium
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top